Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients

被引：0
|
作者：
Grech, C. [1 ]
Hackner, K. [2 ]
Strieder, M. [2 ]
Buder, A. [1 ]
Hochmair, M. J. [3 ,4 ]
Filipits, M. [1 ]
Errhalt, P. [2 ]
机构：
[1] Med Univ Vienna, Ctr Comprehens Canc, Dept Med 1, Inst Canc Res, Vienna, Austria
[2] Karl Landsteiner Univ Hlth Sci, Univ Hosp Krems, Dept Pneumol, Krems, Austria
[3] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria
[4] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1417P
引用
收藏
页码：578 / 578
页数：1
相关论文
共 50 条
  • [21] Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients
    Zhang, Hao
    He, Bin
    Cui, Jun
    Zhao, Mingzhang
    Zhang, Zengwang
    CANCER BIOMARKERS, 2018, 23 (03) : 427 - 436
  • [22] EGFR MUTATION STATUS IN PAIRED PLASMA AND TISSUE SAMPLES OF 93 NSCLC PATIENTS FROM CHINA
    Zhao, Xiao
    Wang, Meng Z.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S674 - S674
  • [23] Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result
    Hong, Yaping
    Zhuang, Wu
    Lai, Jinhuo
    Xu, Haipeng
    He, Yueming
    Lin, Jinlan
    Shi, Qin
    Chen, Shengjia
    Huang, Zhangzhou
    Chen, Shijie
    Lu, Dongzhu
    Lin, Gen
    Huang, Yunjian
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [24] Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
    Baldacci, Simon
    Mazieres, Julien
    Tomasini, Pascale
    Girard, Nicolas
    Guisier, Florian
    Audigier-Valette, Clarisse
    Monnet, Isabelle
    Wislez, Marie
    Perol, Maurice
    Do, Pascal
    Dansin, Eric
    Leduc, Charlotte
    Leprieur, Etienne Giroux
    Moro-Sibilot, Denis
    Tulasne, David
    Kherrouche, Zoulika
    Labreuche, Julien
    Cortot, Alexis B.
    ONCOTARGET, 2017, 8 (62) : 105103 - 105114
  • [25] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Yu, Zhuchen
    Xu, Fei
    Zou, Juntao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (04) : 505 - 517
  • [26] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Zhuchen Yu
    Fei Xu
    Juntao Zou
    European Journal of Clinical Pharmacology, 2024, 80 : 505 - 517
  • [27] Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumour DNA
    Hsu, W. F.
    Ho, H-L.
    Chiang, C. L.
    Jiang, Y.
    Karwowska, S. M.
    Yerram, R.
    Sharma, K.
    Sharma, A.
    Scudder, S.
    Tsai, C-M.
    Palma, J.
    Chiu, C-H.
    Chou, T-Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 643 - 643
  • [28] Plasma metabolite biomarkers for EGFR-mutated non-small cell lung cancer (NSCLC)
    Thamlikitkul, Lucksamon
    Manocheewa, Siriphan
    Limjiasahapong, Suphitcha
    Wanichthanarak, Kwanjeera
    Panya, Atikorn
    Poungvarin, Naravat
    Pomyen, Yotsawat
    Khoomrung, Sakda
    CANCER RESEARCH, 2024, 84 (06)
  • [29] Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
    Dong, Song
    Yan, Bingfa
    Liu, Si-Yang
    Gao, Xuan
    Hong, Hui-Zhao
    Li, Hong-Ji
    Gao, Wei
    Yan, Hong-Hong
    Liu, Si-Yang Maggie
    Tu, Hai-Yan
    Pan, Yi
    Zhou, Qing
    Yang, Xue-Ning
    Xia, Xue-Feng
    Yi, Xin
    Zhong, Wen-Zhao
    Wu, Yi-Long
    Zhang, Jia-Tao
    JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (01):
  • [30] Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib
    Wu, Chen-Te
    Hsu, Ping-Chih
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Wu, Chiao-En
    THORACIC CANCER, 2023, 14 (25) : 2548 - 2557
12345